Cingulates Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
CING Stock | USD 4.03 0.18 4.28% |
Roughly 61% of Cingulate's investor base is looking to short. The analysis of the overall investor sentiment regarding Cingulate suggests that many traders are alarmed. The current market sentiment, together with Cingulate's historical and current headlines, can help investors time the market. In addition, many technical investors use Cingulate stock news signals to limit their universe of possible portfolio assets.
Cingulate |
KANSAS CITY, Kan., Oct. 08, 2024 -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulates lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercia
Read at finance.yahoo.com
Cingulate Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cingulate can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cingulate Fundamental Analysis
We analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Cingulate is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Cingulate Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cingulate stock to make a market-neutral strategy. Peer analysis of Cingulate could also be used in its relative valuation, which is a method of valuing Cingulate by comparing valuation metrics with similar companies.
Peers
Cingulate Related Equities
MNPR | Monopar Therapeutics | 3.78 | ||||
IKT | Inhibikase Therapeutics | 3.78 | ||||
GNLX | Genelux Common | 1.29 | ||||
AVTE | Aerovate Therapeutics | 1.19 | ||||
ACRV | Acrivon Therapeutics, | 0.85 | ||||
PMVP | Pmv Pharmaceuticals | 1.27 | ||||
ADAG | Adagene | 1.46 | ||||
RZLT | Rezolute | 2.18 | ||||
ANTX | AN2 Therapeutics | 5.59 | ||||
ANEB | Anebulo Pharmaceuticals | 7.14 | ||||
SNTI | Senti Biosciences | 8.26 | ||||
DYAI | Dyadic International | 8.59 |
Complementary Tools for Cingulate Stock analysis
When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |